

Help

Bloomberg

Company In Depth Fundamentals - Profile

Ticker: [TRS US EQUITY](#)

Viatris Inc (NASDAQ GS: VTRS, Currency: USD)

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website: www.viatris.com/en
 Number of Employees: 37,000
 Ticker: VTRS US


1000 Mylan Blvd Canonsburg, PA 15317 United States
 Phone : 1-724-514-1800
 Fax : --

↑ 10.23 +0.50 (5.09%)

Viatris Inc. opera como una empresa farmacéutica. Produce medicamentos para pacientes en varias áreas terapéuticas principales que abarcan enfermedades no transmisibles e infecciosas. Atiende a pacientes en todo el mundo.

Stock Quote & Chart (Currency: USD)

Last (delayed quote)	10.25	Market Cap (MM)	12,420.3
Open	10.18	Shares Out. (MM)	1,212.3
Previous Close	9.73	Float %	99.7%
Change	0.11	Shares sold short (MM)	27,474,333.0
Change %	1.14	Dividend Yield %	4.5
Day High/Day Low	10.6 / 10.1	Diluted EPS Excl. XO	1.8
52 Wk High/52 Wk low	15.6 / 9.4	P / Diluted EPS Before XO	16.3
Volume (MM)	21.52	Beta	0.84
Avg. Vol - 3 mo (MM)	11.66		



Financial Information (Currency: USD, in mm)

Revenue - LTM	17,186.7	Cash & ST Invst.	739
EBIT - LTM	1,536.1	Total Assets	54,842.8
EBITDA - LTM	4,761.3	Total Debt	23,375.2
Net Income - LTM	760.8	Total Liabilities	34,350.1
Total Enterprise Value	31,736	Total Equity	20,492.7
TEV/ Total Revenue	1.9 x	Cash from Operations - LTM	3,549.7
TEV/ EBITDA	6.7 x	Cash From Investing - LTM	-488.1
		Cash from Financing -LTM	-2,941.3

Company Notes

A gain of \$20.200 from Legal Expense
 A gain of \$67.800 from Sale of Investments

2014 Q4
 GAAP Net Income Includes: (in millions, pre-tax)
 A gain of \$2.400 from Sale of Business
 A gain of \$67.800 from Sale of Investments

2014 Q1
 GAAP Net Income includes, (in millions, pre-tax):
 a gain of \$20.200 from Legal/Litigation/Settlement

2013 A1
 GAAP Net Income Includes: (in millions, pre-tax)
 A loss of \$2,784.100 from Legal Expense
 A gain of \$81.100 from Sale of Business

2013 Q4
 GAAP Net Income Includes: (in millions, pre-tax)
 A loss of \$2,784.100 from Legal Expense
 A gain of \$-45.900 from Sale of Business

2013 Q2
 GAAP Net Income Includes: (in millions, pre-tax)
 A gain of \$35.200 from Sale of Business

2011 A1
 GAAP Net Income includes, (in millions, pre-tax):
 a gain of \$30.200 from Sale of Properties


Key Board Members

Name	Title	Organization
W Don Cornwell	Co-Founder	Granite Broadcasting Corp
	Board Member	Viатris Inc
	Board Member	Natura & Co Holding Sa
	Board Member	American Intl Group Inc
Neil F Dimick	Trustee	Edna Mcconnell Clark Foundatio
	Board Member	Viатris Inc
	Board Member	Resources Connection Inc
	Board Member	Centerview Capital Holdings LI
James Marshall Kilts "Jim"	Founding Partner/Co-Founder	Centerview Partners
	Founding Partner	Conyers Park Iii Acquisition C
	Co-Ceo	Advantage Solutions Inc
	Lead Director	Viатris Inc
Ian C Read	Board Member	Simply Good Foods Co/The
	Chairman	University Of Chicago
	Trustee	Cato Inst
	Board Member	Operating Executive:Global Health
Harry A Korman "Hal"	Chairman/Co-Founder	Carlyle Group Inc/The
	Chairman	Population Health Investment C
	Board Member	Trinetx Inc
	Board Member	Viатris Inc
Joellen Lyons Dillon	Board Member	Avateramedical Nv
	Board Member	Pharmaceutical Research And Ma
	Board Member	Viатris Inc
	Chairman	Antares Capital Corp
Melina E Higgins	Chairman	Antares Capital Lp
	Chairman	Genworth Financial Inc
	Chairman	Viатris Inc
	Board Member	Mylan Pharmaceuticals
Robert J Coury	Founder	Coury Consulting Lp

Ticker: VTRS US EQUITY		Viartis Inc										
Period Type: Annuals		Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos										
Annuals												
FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY	


Key Financials	Actuals											LTM		Estimates	
	For the Fiscal Period Ending	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/03/2022	30/06/2022	31/12/2022	31/12/2023	31/12/2024			
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	
Total Revenue	9,429.3	11,076.9	11,907.7	11,433.9	11,500.5	USD31/12/2020	USD31/03/2022	USD30/06/2022	USD31/12/2022	4,298.8	4,298.8				
<i>Growth Over Prior Year</i>	22.1%	17.5%	7.5%	(4.0%)	0.6%	3.9%	49.7%	10.1%	(5.2%)	(5.2%)	(5.2%)				
Gross Profit	4,216.1	4,697.0	4,783.1	4,001.6	3,897.6	3,796.7	5,575.5	6,595.0	--	--	--				
<i>Margin %</i>	44.7%	42.4%	40.2%	35.0%	33.9%	--	--	--	--	--	--				
EBITDA	2,493.0	2,224.6	3,242.9	3,015.5	2,734.8	2,086.0	4,570.1	4,761.3	1,459.8	1,459.8	1,459.8				
<i>Margin %</i>	26.4%	20.1%	27.2%	26.4%	23.8%	--	--	--	--	34.0%	34.0%				
EBIT	1,460.9	701.6	1,437.1	905.6	715.5	(210.8)	(34.0)	1,536.1	1,413.8	1,413.8	1,413.8				
<i>Margin %</i>	15.5%	6.3%	12.1%	7.9%	6.2%	--	--	--	--	32.9%	32.9%				
Earnings from Cont. Ops.	847.7	480.0	696.0	352.5	16.8	(669.9)	(1,269.1)	760.8	--	--	--				
<i>Margin %</i>	9.0%	4.3%	5.8%	3.1%	0.1%	--	--	--	--	--	--				
Net Income	847.6	480.0	696.0	352.5	16.8	(669.9)	(1,269.1)	760.8	1,037.4	1,037.4	1,037.4				
<i>Margin %</i>	9.0%	4.3%	5.8%	3.1%	0.1%	--	--	--	--	24.1%	24.1%				
Diluted EPS Excl. Extra Items	1.7	0.9	1.3	0.7	0.0	(1.1)	(1.1)	0.6	0.9	0.9	0.9				
<i>Growth Over Prior Year</i>	(27.4%)	(45.9%)	41.3%	(47.7%)	(95.6%)	--	5.4%	(135.0%)	(13.1%)	(13.1%)	(13.1%)				

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	10.25
Shares Out.	1,212.33
Market Capitalization (USD)	12,426.35
- Cash & Short Term Investments	664.70
+ Total Debt	19,974.60
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	31,736.25
Book Value of Common Equity	19,805.40
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	19,974.60
= Total Capital	39,780.00



Valuation Multiples based on Current Capitalization					
For the Fiscal Period Ending	Actual		Estimates		
	31/03/2022	30/06/2022	31/03/2022	31/03/2022	31/03/2022
TEV/Total Revenue	2.2x	1.9x	7.4x	7.4x	7.4x
TEV/EBITDA	8.5x	6.7x	5.2x	5.2x	5.2x
TEV/EBIT	--	20.8x	5.7x	5.7x	5.7x
P/Diluted EPS Before Extra	--	16.6x	--	--	--
P/BV	0.8x	0.6x	0.6x	0.6x	0.6x
Price/Tang BV	--	--	--	--	--

Valuation Multiples for Chart				
For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	5.6x	3.0x	3.0x	3.0x
TEV / EBITDA	6.7x	5.2x	5.2x	5.2x
Price / CF	3.5x	0.0x	0.0x	0.0x
Price / Book	0.6x	0.6x	0.6x	0.6x
Dividend Yield	4.5x	4.7x	4.7x	4.7x



Ticker:	VTRS US EQUITY
Period Type	Annuals

VTRS US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Viatri Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Income Statement											
Income Sheet as of:											
Currency	31/12/2011 USD	31/12/2012 USD	31/12/2013 USD	31/12/2014 USD	31/12/2015 USD	31/12/2016 USD	31/12/2017 USD	31/12/2018 USD	31/12/2019 USD	31/12/2020 USD	31/12/2021 USD
Revenue	6,106.28	6,750.20	6,856.60	7,646.50	9,362.60	10,967.10	11,760.00	11,268.70	11,370.30	11,819.90	17,813.60
Other Revenue	23.55	45.90	52.50	73.10	66.70	109.80	147.70	165.20	130.20	126.10	72.70
Total Revenue	6,129.83	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30
Cost Of Goods Sold	3,566.46	3,887.80	3,868.80	4,191.60	5,213.20	6,379.90	7,124.60	7,432.30	7,602.90	8,149.30	12,310.80
Gross Profit	2,563.36	2,908.30	3,040.30	3,528.00	4,216.10	4,697.00	4,783.10	4,001.60	3,897.60	3,796.70	5,575.50
Selling General & Admin Exp.	1,263.19	1,397.60	1,397.00	1,593.60	2,083.30	3,168.60	2,562.70	2,391.50	2,542.20	3,452.40	4,858.40
R & D Exp.	294.73	401.30	507.80	581.80	671.90	826.80	783.30	704.50	639.90	555.10	751.10
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense., Total	1,557.92	1,798.90	1,904.80	2,175.40	2,755.20	3,995.40	3,346.00	3,096.00	3,182.10	4,007.50	5,609.50
Operating Income	1,005.45	1,109.40	1,135.50	1,352.60	1,460.90	701.60	1,437.10	905.60	715.50	(210.80)	(34.00)
Interest Expense	335.94	308.70	313.30	333.20	339.40	454.80	534.60	542.30	517.30	497.80	636.20
Interest Income	-	-	-	-	-	-	-	-	-	-	-
Net Interest Exp.	335.94	308.70	313.30	333.20	339.40	454.80	534.60	542.30	517.30	497.80	636.20
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	14.87	(3.50)	74.90	44.90	206.10	125.10	(0.50)	64.90	43.80	12.60	(5.80)
EBT Excl. Unusual Items	654.64	804.20	747.30	974.50	915.40	121.70	903.00	298.40	154.40	(721.20)	(664.40)
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
EBT Incl. Unusual Items	654.64	804.20	747.30	974.50	915.40	121.70	903.00	298.40	154.40	(721.20)	(664.40)
Income Tax Expense	115.83	161.20	120.80	41.40	67.70	(358.30)	207.00	(54.10)	137.60	(51.30)	604.70
Earnings from Cont. Ops.	538.80	643.00	626.50	933.10	847.70	480.00	696.00	352.50	16.80	(669.90)	(1,269.10)
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	-	-	-
Minority Int. in Earnings	1.99	2.10	2.80	3.70	0.10	-	-	-	-	-	-
Net Income	536.81	640.90	623.70	929.40	847.60	480.00	696.00	352.50	16.80	(669.90)	(1,269.10)
Pref. Dividends	-	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	536.81	640.90	623.70	929.40	847.60	480.00	696.00	352.50	16.80	(669.90)	(1,269.10)
Abnormal Losses (Gains)	105.66	234.80	328.46	413.00	744.70	1,543.90	629.60	742.90	820.00	1,618.60	1,992.30
Tax Effect on Abnormal Items	(41.07)	(76.56)	(103.79)	(190.84)	(170.02)	(439.11)	(114.69)	(162.75)	(117.89)	(89.95)	742.12
NI to Common Excl. Extra Items	601.39	799.14	848.37	1,151.56	1,422.28	1,584.79	1,210.91	932.65	718.91	858.75	1,465.32
Per Share Items											
Basic EPS	1.25	1.54	1.63	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)	(1.05)
Basic EPS Excl. Extra Items	1.25	1.54	1.63	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)	(1.05)
Weighted Avg. Basic Shares Out.	430.84	415.20	383.30	373.70	472.20	513.00	534.50	514.50	515.70	601.20	1,208.80
Diluted EPS	1.22	1.52	1.58	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)	(1.05)
Diluted EPS Excl. Extra Items	1.22	1.52	1.58	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)	(1.05)
Weighted Avg. Diluted Shares Out.	438.79	420.20	394.50	398.00	497.40	520.50	536.70	516.50	516.50	601.20	1,208.80
Normalized Basic EPS	2.04	2.59	2.89	3.56	4.30	4.89	4.56	4.58	4.42	3.95	3.70
Normalized Diluted EPS	1.37	1.90	2.15	2.90	2.86	3.04	2.26	1.80	1.39	1.43	1.21
Dividends per Share	-	-	-	-	-	-	-	-	-	-	0.33
Payout Ratio %	-	-	-	-	-	-	-	-	-	-	-
Supplemental Items											
EBITA	1,363.34	1,495.80	1,499.20	1,746.40	2,306.90	1,965.20	2,955.30	2,739.50	2,482.70	1,796.30	4,060.60
EBIT	1,005.45	1,109.40	1,135.50	1,352.60	1,460.90	701.60	1,437.10	905.60	715.50	(210.80)	(34.00)
As Reported Total Revenue*	6,129.83	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30
Effective Tax Rate %	17.69	20.04	16.16	4.25	7.40	-	22.92	-	89.12	-	-
Normalized Net Income	601.39	799.14	848.37	1,151.56	1,422.28	1,584.79	1,210.91	932.65	718.91	858.75	1,465.32
Interest Capitalized	-	-	-	-	-	-	-	-	-	-	-
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	42.58	42.60	47.00	66.00	92.80	88.90	74.70	-	-	79.20	111.20
Stock-Based Comp., Total	42.58	42.60	47.00	66.00	92.80	88.90	74.70	-	-	79.20	111.20

Ticker:	VTRS US EQUITY
Period Type	Annuals

VTRS US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Viatri Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Balance Sheet											
Balance Sheet as of:	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	375.06	349.97	291.30	225.50	1,236.00	998.80	292.10	388.10	475.60	844.40	701.20
Short Term Investments	30.69	-	-	-	-	83.70	76.70	-	-	39.10	38.20
Total Cash & ST Investments	405.74	349.97	291.30	225.50	1,236.00	1,082.50	368.80	388.10	475.60	883.50	739.40
Accounts & Notes Receivable	1,426.44	1,554.34	1,820.00	2,268.50	2,689.10	3,015.40	3,173.10	2,881.00	3,058.80	3,891.30	3,774.40
Total Receivables	1,426.44	1,554.34	1,820.00	2,268.50	2,689.10	3,015.40	3,173.10	2,881.00	3,058.80	3,891.30	3,774.40
Inventories	1,396.74	1,525.24	1,656.90	1,651.40	1,951.00	2,456.40	2,542.70	2,580.20	2,670.90	5,471.90	3,977.70
Prepaid Exp.	127.75	243.82	452.90	2,295.80	596.60	756.40	766.10	518.40	552.00	1,707.40	1,957.60
Restricted Cash	9.27	-	-	-	-	-	-	-	-	-	-
Other Current Assets	202.90	229.35	250.10	-	-	211.80	362.60	-	-	913.40	453.80
Total Current Assets	3,568.84	3,902.72	4,471.20	6,441.20	6,472.70	7,522.50	7,213.30	6,367.70	6,757.30	12,867.50	10,902.90
Net Property, Plant & Equipment	1,298.03	1,397.22	1,665.50	1,785.70	1,983.90	2,322.20	2,339.10	-	-	3,783.50	3,479.40
Long-term Investments	-	-	-	-	-	-	-	-	-	-	-
Deferred Charges, LT	39.38	87.66	77.80	397.40	457.60	633.20	496.80	-	-	2,147.90	1,332.70
Other Long-Term Assets	6,691.89	6,544.31	9,080.30	7,196.20	13,353.50	24,248.30	25,757.10	26,367.20	24,498.20	42,754.10	39,127.80
Total Assets	11,598.14	11,931.90	15,294.80	15,820.50	22,267.70	34,726.20	35,806.30	32,734.90	31,255.50	61,553.00	54,842.80
LIABILITIES											
Accrued Exp.	-	-	-	-	-	-	-	-	-	-	-
Short-term Borrowings	819.67	397.04	443.40	2,803.60	1,078.30	336.40	1,855.40	699.80	1,508.10	3,502.30	3,457.20
Accounts Payable	703.24	777.91	1,072.80	905.60	1,109.60	1,348.10	1,452.50	-	-	1,904.20	1,657.40
Curr. Income Taxes Payable	42.88	33.73	49.70	160.70	92.40	97.70	112.90	-	-	288.60	236.90
Other Current Liabilities	997.37	984.83	1,398.10	1,434.10	1,841.90	3,258.50	2,964.50	3,888.00	4,061.00	4,867.80	4,532.90
Total Current Liabilities	2,563.16	2,193.50	2,964.00	5,304.00	4,122.20	5,040.70	6,385.30	4,587.80	5,569.10	10,562.90	9,884.40
Long-Term Debt	4,019.08	4,700.90	7,586.50	3,846.40	6,295.60	15,202.90	12,865.30	13,161.20	11,214.30	22,658.70	19,918.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	1,511.13	1,681.67	1,784.40	3,394.10	2,084.10	3,365.00	3,248.10	2,818.80	2,588.30	5,377.30	4,547.70
Total Liabilities	8,093.36	8,576.07	12,334.90	12,544.50	12,501.90	23,608.60	22,498.70	20,567.80	19,371.70	38,598.90	34,350.10
Pref. Stock, Non-Redeem.	-	-	-	-	-	-	-	-	-	-	-
Total Pref. Equity	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	13.01	15.11	18.10	20.10	1.40	1.40	-	-	-	-	-
Additional Paid In Capital	4,060.53	4,256.58	4,375.60	4,486.10	7,134.10	8,505.30	8,592.00	-	-	18,450.90	18,548.20
Retained Earnings	1,420.52	2,061.37	2,685.10	3,614.50	4,462.10	4,942.10	5,644.50	-	-	5,361.20	3,688.80
Treasury Stock	(1,901.44)	(2,890.73)	(3,878.80)	(3,857.70)	(67.50)	(67.50)	(567.70)	-	-	-	-
Comprehensive Inc. and Other	(87.84)	(86.50)	(240.10)	(987.00)	(1,764.30)	(2,263.70)	(361.20)	12,167.10	11,883.80	(858.00)	(1,744.30)
Total Common Equity	3,504.78	3,355.83	2,959.90	3,276.00	9,765.80	11,117.60	13,307.60	12,167.10	11,883.80	22,954.10	20,492.70
Total Equity	3,504.78	3,355.83	2,959.90	3,276.00	9,765.80	11,117.60	13,307.60	12,167.10	11,883.80	22,954.10	20,492.70
Total Liabilities And Equity	11,598.14	11,931.90	15,294.80	15,820.50	22,267.70	34,726.20	35,806.30	32,734.90	31,255.50	61,553.00	54,842.80
Supplemental Items											
Total Shares Out. on Filing Date	426.68	395.21	371.60	375.22	490.62	535.33	524.21	515.63	516.18	1,206.90	1,209.51
Total Shares Out. on Balance Sheet Date	426.68	395.21	371.60	375.22	490.62	535.33	524.21	515.63	516.18	1,206.90	1,209.51
Book Value/Share	8.18	8.45	7.92	8.68	19.90	20.77	25.39	23.60	23.02	19.02	16.94
Tangible Book Value	(2,656.91)	(2,399.39)	(3,916.60)	(3,140.50)	(2,837.60)	(12,563.50)	(12,143.90)	(11,245.30)	(9,356.70)	(19,076.10)	(17,755.20)
Tangible Book Value/Share	(6.23)	(6.07)	(10.54)	(8.37)	(5.78)	(23.47)	(23.17)	(21.81)	(18.13)	(15.81)	(14.68)
Total Debt	4,838.75	5,097.93	8,029.90	6,650.00	7,373.90	15,539.30	14,720.70	13,861.00	12,722.40	26,161.00	23,375.20
Net Debt	4,433.01	4,747.96	7,738.60	6,424.50	6,137.90	14,456.80	14,351.90	13,472.90	12,246.80	25,277.50	22,635.80
Total Minority Interest	13.01	15.11	18.10	20.10	1.40	1.40	-	-	-	-	-
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	370.42	455.96	482.80	549.50	592.40	783.40	895.50	-	-	958.40	922.40
Work in Progress Inventory	253.49	268.19	310.00	298.40	387.00	436.00	384.70	-	-	1,438.10	993.30
Finished Goods Inventory	772.83	801.09	864.10	803.50	971.60	1,237.00	1,262.50	-	-	3,075.40	2,062.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	18.93	23.04	24.60	25.70	33.60	59.00	75.30	-	-	159.90	154.50
Full Time Employees	-	-	20,000.00	30,000.00	35,000.00	35,000.00	35,000.00	35,000.00	35,000.00	45,000.00	37,000.00

Ticker: VTRS US EQUITY	VTRS US EQUITY Ascend	Currency <input type="checkbox"/> Reporting <input checked="" type="checkbox"/> Change	USD
Period Type: Annuals	Consolidated: Yes	Accounting: Mixed	

Viatis Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
REVENUE											
Revenue by Product											
For the Fiscal Period Ending	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Revenue	6,129.83	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30
Brands	5,579.30	5,946.20	5,900.70	6,510.40	8,429.30	10,967.10	11,760.00	11,268.70	11,370.30	5,289.50	10,841.30
Generics	584.85	849.90	1,008.50	51.10	-	109.80	-	165.20	130.20	5,234.90	5,630.20
Complex Generics & Biosimilars	-	-	-	-	-	-	-	-	-	1,295.50	1,342.10
Other Sources	-	-	-	-	-	-	-	-	-	126.10	72.70
#/N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#/N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#/N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
Viagra	-	-	-	-	-	-	-	-	-	-	-
EpiPen Auto-Injectors	-	-	-	-	-	-	-	-	-	-	-
Celebrex	-	-	-	-	-	-	-	-	-	-	-
Revenue by Geography											
For the Fiscal Period Ending	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Revenue	6,129.83	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30
Developed Markets	3,449.88	4,060.70	3,988.30	4,548.40	5,100.40	5,629.50	4,969.60	4,157.30	4,164.10	8,510.90	10,428.70
Emerging Markets	1,781.18	1,391.90	1,438.60	1,621.30	2,205.60	2,953.80	3,958.30	4,095.60	4,037.10	1,853.80	3,144.70
Greater China	875.21	1,297.60	1,429.70	1,476.80	2,056.60	2,383.80	2,832.10	3,015.80	3,169.10	1,195.30	2,212.80
Japan, Australia & New Zealand (JANZ)	23.55	45.90	52.50	73.10	66.70	109.80	147.70	165.20	130.20	259.90	2,027.40
#/N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	126.10	72.70
#/N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#/N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#/N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#/N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#/N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#/N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Ticker: VTRS US EQUITY	Sort Ascend	Currency Reporting Change USD
Period Type: Annuals	Consolidated: Yes	Accounting: Mixed

Viatis Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Pension											
For the Fiscal Period Ending	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	--	--	--	5.00	11.90	17.40	20.10	--	--	23.50	38.60
Interest Cost	--	--	--	2.60	4.00	8.20	13.60	--	--	13.50	31.60
Expected Return on Plan Assets	--	--	--	(1.70)	(6.40)	(10.90)	(14.30)	--	--	(19.90)	(66.10)
Pension Expense (Income)	-	-	-	7.00	11.80	13.40	18.20	--	--	18.60	(10.20)
Other Postretirement Cost											
Service Cost	--	--	--	0.50	0.60	0.60	0.70	--	--	1.20	3.40
Interest Cost	--	--	--	1.00	1.10	1.30	1.60	--	--	1.40	2.60
Expected Return on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Other Postretirement Benefits Expense (I)	-	-	-	-	-	-	-	--	--	2.90	6.20
Pension Funded Status											
Fair Value of Plan Assets	--	--	--	--	162.00	291.70	296.10	--	--	1,354.60	1,366.40
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	--	--	--	--	--	58.20	97.00
Benefits Paid	--	--	--	--	--	--	--	--	--	(24.60)	(52.80)
Projected Benefit Obligation	--	--	--	--	234.40	632.90	665.20	--	--	2,145.80	1,946.60
Over(Under) Funded Pension	--	--	--	--	(72.40)	(341.20)	(369.10)	--	--	(791.20)	(580.20)
Accumulated Benefit Obligation	--	--	--	--	--	--	--	--	--	--	--
Pension Funding Ratio	--	--	--	--	69.11	46.09	44.51	--	--	63.13	70.19
Other Postretirement Funded Status											
Fair Value of Plan Assets	--	--	--	--	-	-	-	--	--	-	-
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	--	--	--	--	--	1.70	18.30
Benefits Paid	--	--	--	(1.60)	(2.00)	(2.20)	(2.70)	--	--	(1.60)	(20.70)
Projected Benefit Obligation	--	--	--	--	--	--	--	--	--	188.80	188.40
Over(Under) Funded Post Ret Benefits	--	--	--	--	(26.00)	(38.00)	(35.10)	--	--	(188.80)	(188.40)
Other Post-Retirement Funding Ratio	--	--	--	--	--	--	--	--	--	--	--
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	--	--	--	--	--	--	--	--	--	4.30	5.10
Discount Rate used on Plan Liabilities	--	--	--	--	--	--	--	--	--	1.90	2.30
Rate of Compensation Increase	--	--	--	--	--	--	--	--	--	2.90	3.10
Other Postretirement Benefits											
Expected Return on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Discount Rate used on Plan Liabilities	--	--	--	--	--	--	--	--	--	3.30	1.90
Health Care Cost Trend Projected(next y	--	--	--	--	--	--	--	--	--	--	--
Pension Plan Asset Allocation											
Fair Value of Plan Assets	--	--	--	--	162.00	291.70	296.10	--	--	1,354.60	1,366.40
Asset Category - Equities %	--	--	--	--	--	--	--	--	--	45.28	40.33
Asset Category - Debt %	--	--	--	--	--	--	--	--	--	43.70	45.15
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	--	--	--	--	--	--	--	--	--	3.82	4.76
Asset Category - Other %	--	--	--	--	--	--	--	--	--	7.19	9.76
Expected Pension Payments											
Year 1	--	--	--	--	--	--	--	--	--	104.50	101.80
Year 2	--	--	--	--	--	--	--	--	--	102.30	97.10
Year 3	--	--	--	--	--	--	--	--	--	104.90	103.00
Year 4	--	--	--	--	--	--	--	--	--	108.60	100.70
Year 5	--	--	--	--	--	--	--	--	--	106.90	104.30
Beyond Year 5	--	--	--	--	--	--	--	--	--	526.20	528.50
Expected Postretirement Benefits											
Year 1	--	--	--	--	--	--	--	--	--	16.40	16.10
Year 2	--	--	--	--	--	--	--	--	--	16.60	16.50
Year 3	--	--	--	--	--	--	--	--	--	16.50	16.90
Year 4	--	--	--	--	--	--	--	--	--	16.60	16.80
Year 5	--	--	--	--	--	--	--	--	--	16.30	16.60
Beyond Year 5	--	--	--	--	--	--	--	--	--	71.40	73.00

Ticker: **VTRS US EQUITY** Sort: **Ascend** Currency: **Reporting** Change: **USD**
 Period Type: **Annuals** Consolidated: **Yes** Accounting: **Mixed**

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Supplemental											
For the Fiscal Period Ending	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Options Activity											
Options Granted During Period	4.94	3.13	2.18	6.23	0.94	0.88	0.96	-	-	0.81	-
Options Outstanding End Of Period	23.60	16.62	13.56	16.21	7.73	7.70	7.20	-	-	6.71	5.58
Options Exercisable End of Period	15.58	9.37	8.01	7.65	5.15	5.67	5.54	-	-	5.28	4.97
Price											
Weighted Average Fair Value per Option	-	7.00	8.49	17.44	20.18	17.90	15.88	-	-	8.07	-
Avg Exercise Price (Options Outstanding)	17.42	19.54	22.05	33.21	31.85	33.38	35.17	-	-	35.36	37.19
Avg Exercise Price (Options Exercisable)	16.05	17.57	18.82	20.42	23.56	28.10	31.99	-	-	38.51	39.21
Stock Option Valuation Model	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	1.00	1.00
Assumptions											
Stock Opt Valuation - Risk Free Rate (%)	-	1.00	1.10	1.90	1.70	1.40	2.20	-	-	1.00	-
Stock Opt Valuation - Expected Life (Yrs)	-	5.90	6.10	6.30	6.30	6.30	6.40	-	-	6.50	-
Stock Opt Valuation - Expected Volatil (%)	-	29.70	23.90	31.60	33.70	38.10	33.20	-	-	46.70	-
Stock Opt Valuation - Dividend Yield (%)	-	-	-	-	-	-	-	-	-	-	-
Stock Expense											
Expense For Stock-Based Compensation	42.58	42.60	47.00	66.00	92.80	88.90	74.70	-	56.80	79.20	111.20
Stock Option Expense (After Tax)	-	-	-	-	-	-	-	-	-	-	-